Dr. Bogdana Schmidt

Is there any patient population or anything, just knowing, obviously, cross-trial comparisons are so fraught with so many problems, but is there any patient population for whom you might say, maybe nivolumab, we have slightly better data for? Or do you feel like the dosing schedule of Pembro kind of trumps things?

Is there any patient population or anything, just knowing, obviously, cross-trial comparisons are so fraught with so many problems, but is there any patient population for whom you might say, maybe nivolumab, we have slightly better data for? Or do you feel like the dosing schedule of Pembro kind of trumps things?

Excellent. And I think you and all of our, I think, medical oncology colleagues have been using pembrolizumab for its numerous indications. So I think that the comfort level certainly is really interesting. Can you comment a little bit about upper tract disease?

Excellent. And I think you and all of our, I think, medical oncology colleagues have been using pembrolizumab for its numerous indications. So I think that the comfort level certainly is really interesting. Can you comment a little bit about upper tract disease?

Excellent. And I think you and all of our, I think, medical oncology colleagues have been using pembrolizumab for its numerous indications. So I think that the comfort level certainly is really interesting. Can you comment a little bit about upper tract disease?

We want something. We certainly all want something.

We want something. We certainly all want something.

We want something. We certainly all want something.

So now to just put a point on what you just made. So let's say you have a patient who refused cisplatin up front, not, you know, didn't get Niagara Protocol. Post-op, would you still be trying to engage in chemo or checkpoint if they're eligible but refused? Would you be trying to tackle that refusal for the second time or no?

So now to just put a point on what you just made. So let's say you have a patient who refused cisplatin up front, not, you know, didn't get Niagara Protocol. Post-op, would you still be trying to engage in chemo or checkpoint if they're eligible but refused? Would you be trying to tackle that refusal for the second time or no?

So now to just put a point on what you just made. So let's say you have a patient who refused cisplatin up front, not, you know, didn't get Niagara Protocol. Post-op, would you still be trying to engage in chemo or checkpoint if they're eligible but refused? Would you be trying to tackle that refusal for the second time or no?

From a cup now at the NIH, this may be less of a point for you guys, but let's say a patient refuses adjuvant chemo at this point. Are you able to offer them checkpoint inhibitor in lieu of it? Oh, yes, of course. Because I know that some folks will say that they can't get insurance approval for it if they're CIS eligible. But obviously, at the NIH, this is less of an issue.

From a cup now at the NIH, this may be less of a point for you guys, but let's say a patient refuses adjuvant chemo at this point. Are you able to offer them checkpoint inhibitor in lieu of it? Oh, yes, of course. Because I know that some folks will say that they can't get insurance approval for it if they're CIS eligible. But obviously, at the NIH, this is less of an issue.

From a cup now at the NIH, this may be less of a point for you guys, but let's say a patient refuses adjuvant chemo at this point. Are you able to offer them checkpoint inhibitor in lieu of it? Oh, yes, of course. Because I know that some folks will say that they can't get insurance approval for it if they're CIS eligible. But obviously, at the NIH, this is less of an issue.

And I know there are ways to get our patients what we think is in their best interest. But even with all of this immunotherapy data, When patients didn't get cisplatin up front, we're still sort of advocating for cisplatin adjuvately because that's what we have the strongest longitudinal data for. So I'm sure that space will continue to evolve. Now, you almost led me straight to the...

And I know there are ways to get our patients what we think is in their best interest. But even with all of this immunotherapy data, When patients didn't get cisplatin up front, we're still sort of advocating for cisplatin adjuvately because that's what we have the strongest longitudinal data for. So I'm sure that space will continue to evolve. Now, you almost led me straight to the...

And I know there are ways to get our patients what we think is in their best interest. But even with all of this immunotherapy data, When patients didn't get cisplatin up front, we're still sort of advocating for cisplatin adjuvately because that's what we have the strongest longitudinal data for. So I'm sure that space will continue to evolve. Now, you almost led me straight to the...

to the next topic, which is how are we going to figure out how not to over-treat these patients? Because you mentioned in Niagara, right, we're having patients get dervalumab up front, then chemo, then dervalumab. Now we have ambassador and checkpoint data for just adjuvant, but we also know there are probably

to the next topic, which is how are we going to figure out how not to over-treat these patients? Because you mentioned in Niagara, right, we're having patients get dervalumab up front, then chemo, then dervalumab. Now we have ambassador and checkpoint data for just adjuvant, but we also know there are probably

to the next topic, which is how are we going to figure out how not to over-treat these patients? Because you mentioned in Niagara, right, we're having patients get dervalumab up front, then chemo, then dervalumab. Now we have ambassador and checkpoint data for just adjuvant, but we also know there are probably